Drs. Daniel C. Cattran and Fernando C. Fervenza join ZyVersa's distinguished group of Scientific Advisors VAR 200 is a phase 2a-ready cholesterol efflux mediator in development to ameliorate renal lipid accumulation that damages the kidneys' filtration system, leading to progression of kidney
ZyVersa is a clinical stage biopharmaceutical company developing first-in-class product candidates to address significant unmet medical needs of patients with inflammatory and renal diseases Lead anti-inflammatory product candidate, inflammasome ASC inhibitor IC 100, blocks initiation and
ZyVersa is a clinical stage biopharmaceutical company developing first-in-class product candidates for treatment of renal and inflammatory diseases WESTON, Fla. and BRIDGEWATER, N.J., Dec. 12, 2022 /PRNewswire/ -- ZyVersa Therapeutics, Inc. ("ZyVersa"), a clinical stage specialty biopharmaceutical
Annual Inflammasome Summit unites world renowned experts in inflammasome-targeted drug development and academia to share information and address knowledge gaps in this rapidly evolving field ZyVersa is well positioned in the emerging inflammasome space with a highly differentiated inflammasome ASC
Special meeting of Larkspur stockholders scheduled for December 8, 2022, to vote on the proposed business combination of Larkspur with ZyVersa ZyVersa is a clinical stage biopharmaceutical company with two licensed proprietary product platforms, a cholesterol efflux mediator targeting multiple
Mr. Glover will be joining four other life science executives in a General Session titled, CEO Panel: Learn from the experts ZyVersa is a clinical stage biopharmaceutical company with two licensed proprietary product platforms targeting renal and inflammatory diseases ZyVersa and Larkspur Health
Aggregate committed financing in support of the business combination now at $10.0 million ZyVersa and Larkspur entered into a definitive business combination agreement on July 20, 2022 ZyVersa is a clinical stage biopharmaceutical company developing first-in-class product candidates to address
Age-related chronic inflammation induced by activation of NLRP1 inflammasomes is implicated in development and progression of neurodegenerative diseases such as Alzheimer's and Parkinson's diseases IC 100 research was conducted at the University of Miami Miller School of Medicine by acclaimed
BRIDGEWATER, N.J. and WESTON, Fla., Aug. 15, 2022 /PRNewswire/ -- Larkspur Health Acquisition Corp. (NASDAQ: LSPR or "Larkspur"), a blank-check special purpose acquisition company, and ZyVersa Therapeutics, Inc. ("ZyVersa"), a clinical stage specialty biopharmaceutical company leveraging
IC 100, a novel monoclonal antibody inflammasome ASC inhibitor, targets multiple types of inflammasomes to block initiation and perpetuation of damaging chronic inflammation IC 100 has broad tissue distribution, including CNS and peripheral tissues, is rapidly internalized by a variety of cell
